The Economic Case for Early Screening

As we  pave the way for better patient outcomes with the first minimally invasive microbiome-driven liquid biopsy technology, we also want to make sure that the important economic benefits that health insurance companies will reap from covering early cancer screening...

The Case for Tackling One Cancer at a Time

While having generated a lot of buzz recently, early screening for multiple types of cancer at once may not be that ideal in practice- the path to clinical adoption could be taking on one cancer type at a time. In a perfect world, a simple blood test would catch all...